[176] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions
These drugs draw attention because they treat appetite as biology, not willpower
Medical weight loss programs are one of the most effective and sustainable means of losing excess weight to achieve a healthier weight while reducing the risk of weight-related health conditions
Additionally, these agents slow gastric emptying, which prolongs the sensation of fullness after meals and reduces appetite through effects on brain centres that regulate hunger
Notably, 72% of participants with prediabetes at baseline reverted to normoglycemia during Retatrutide treatment, indicating potential for diabetes prevention in at-risk populations
With compounded GLP-1 therapy, your physician must guide you in determining the correct dosage